WILLIAMSVILLE, N.Y.–(BUSINESS WIRE)–22nd Century Group, Inc. (NYSE American: XXII) (“22nd Century” or “the Company”), a leading plant biotechnology company focused on reduced nicotine tobacco and hemp/cannabis plant genetics research and development, today reported results for the first quarter ended March 31, 2020. “We are very pleased with the solid start to 2020 with revenue increasing 12% over last year. We believe the Company is well positioned to execute on its strategies despite a chal

READ MORE: https://www.businesswire.com/news/home/20200507005215/en/22nd-Century-Group-Reports-Quarter-2020-Financial/?feedref=JjAwJuNHiystnCoBq_hl-W8j9Oi60kFTomUxRDB8jhB8bDel5XZmwWFQYQPHxx__rCOi9QzgjCezTS3Nw_X6kJUrpSBm-Hav1w-UkdSlG3kCXJZE-1b1nXn968wYfofVLkaZDLiczsahzEklD3R10Q==